U.S. President Donald Trump's plan to impose tariffs on generic drugs will lead to patients in the U.S. paying higher prices, warned the CEO of Indian pharmaceutical company Dr Reddy's. Manufacturing ...

The most common prescription drugs you pick up at the pharmacy counter or fill via mail order will likely get more expensive under President Donald Trump's plan to assess a 100% tariff on imported ...

Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...

Imported generic drugs will face a 100 percent tariff beginning in August 2028 unless manufacturers move production to the U.S., President Trump said in a social media post Tuesday. Trump wrote on ...

The administration has repeatedly said it will impose steep pharmaceutical tariffs but has not followed through on them. By Rebecca Robbins President Trump said on Tuesday evening that he planned to ...

President Donald Trump announced Tuesday that imported generic drugs will remain tariff-free for the next two years before facing steep new import duties, saying the move is designed to encourage ...

WASHINGTON, July 21 (Reuters) - President Donald Trump said on Tuesday all generic drugs being brought into the U.S. will continue having ‌a tariff of 0% for two years starting from August 1, after ...

President Donald Trump on Tuesday announced a plan to impose a 100 percent tariff on generic drugs starting in August 2028 as part of a bid to push pharmaceutical production back to the United States.

Imported generic drugs could face tariffs of up to 100% beginning in 2028 under a plan announced Tuesday by President Trump, who said the measure is intended to push manufacturers to move production ...

Trump said generic drugs imported into the U.S. will face zero tariffs for two years from August 1. The rate will rise to 100% in 2028, before doubling a year later. The latest tariff salvo ...

A judge in the US has denied an attempt by Novartis to stop MSN Pharmaceuticals from launching a generic version of heart failure blockbuster Entresto. MSN Pharma was given FDA approval for its ...

While the White House focused its initial Section 232 pharmaceutical tariffs on branded drugs, generics makers—who supply the vast majority of U.S. prescriptions—won’t stay in the clear for long. In ...